Synthesis, structure, DNA binding and anticancer activity of mixed ligand ruthenium(II) complex

Gilewska, Agnieszka; Masternak, Joanna; Kazimierczuk, Katarzyna; Trynda, Justyna; Wietrzyk, Joanna; Barszcz, Barbara

doi:10.1016/j.molstruc.2017.10.105

Cited by 10 publications

(9 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Ru···Cg (Cg denotes the gravity ring center of C(12)–C(13)–C(14)–C(15)–C(16)–C(17)) distance (1.6841(12) Å) ( Table 2 ) as well as the Ru–Cl distance (2.3942(4) Å) and the Ru-N (2.1022(14) and 2.0950(14) Å) bond lengths are similar to other ruthenium complexes [ 8 ]. The six-membered chelate ring Ru(1)–N(1) ∩ N(2) adopted a boat conformation with the Ru(1) and C(6) atoms below the plane at 0.986 and 0.420 Å, respectively.…”

Section: Resultssupporting

confidence: 67%

“…The crystal packing analysis revealed the collection of the intra-and intermolecular short contacts shown in Figure 2 and listed in Table 3. 14and 2.0950(14) Å) bond lengths are similar to other ruthenium complexes [8]. The six-membered chelate ring Ru(1)-N(1) ∩ N(2) adopted a boat conformation with the Ru(1) and C(6) atoms below the plane at 0.986 and 0.420 Å, respectively.…”

Section: Description Of the Structuressupporting

confidence: 65%

“…Unfortunately, while the obtained complex showed moderate activity against the tested carcinoma cells, it was also active against the normal BALB/3T3 cell line (IC 50 = 43.66 µM; but its cytotoxicity is 15 times lower compared with cisplatin) [ 6 ]. Taking this into account, during our following experiments, we tested whether a 2-(2′-pyridyl)benzimidazole replacement with 2,2-bis(4,5-dimethylimidazole) (L 1 ) in an arene ruthenium complex {[RuCl(L 1 )(η 6 - p -cymene)]PF 6 }·2H 2 O [ 8 ] could be a potential chemotherapeutic agent. It displays only moderately cytotoxic activity against the MV-4-11 cell line (IC 50 = 27.34 µM) in vitro but does not affect the normal BALB/3T3 cell line.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Ruthenium(II) and Iridium(III) Complexes as Tested Materials for New Anticancer Agents

et al. 2020

Self Cite

View full text Add to dashboard Cite

The oncological use of cisplatin is hindered by its severe side effects and a very important resistance problem. To overcome these problems, scientists have attempted to design new generation transition-metal anticancer complexes. In this study, we present new complexes, ruthenium(II) [(η6-p-cymene)RuCl(py2CO)]PF6 (1), iridium(III) [(η5-Cp)IrCl(py2CO)]PF6 (2), and NH4[IrCl4(py2CO)]·H2O (3), based on di-2-pyridylketone (py2CO). The prepared complexes were characterized by FTIR, 1H, 13C, 15N NMR, UV-Vis, PL and elemental analysis techniques. The single-crystal X-ray structure analysis and comparative data revealed pseudo-octahedral half-sandwich 1 and 2 complexes and octahedral tetrachloroiridate(III) 3 with a rare chelating κ2N,O coordination mode of py2CO. The compounds were tested in vitro against three cancer cell lines—colorectal adenoma (LoVo), myelomonocytic leukaemia (MV-4-11), breast adenocarcinoma (MCF-7), and normal fibroblasts (BALB/3T3). The most promising results were obtained for iridium(III) complex 3 against MV-4-11 (IC50 = 35.8 ± 13.9 µg/mL) without a toxic effect against normal BALB/3T3, which pointed towards its selectivity as a potential anticancer agent. Extensive research into their mode of binding with DNA confirmed for 1 and 2 complexes non-classical binding modes, while the 3D circular dichroism (CD) experiment (ΔTm) suggested that 3 induced the probable formation of covalent bonds with DNA. In addition, the obtained iridium complexes induce ROS, which, in synergy with hydrolysis promoting DNA bonding, may lead to cancer cell death.

show abstract

Section: Resultssupporting

confidence: 67%

Section: Description Of the Structuressupporting

confidence: 65%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ruthenium(II) and Iridium(III) Complexes as Tested Materials for New Anticancer Agents

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Also, textile dyes, due to containing azo group -N=N-and the conjugated bonds, appear colored by the absorption of light in the visible region [2]. Azo compound derived from heterocyclic amines containing nitrogen in the aromatic rings and their metal complexes, particularly fused with imidazole or pyrazole as the heterocyclic, have been drawing the interest of many studies due to their biological activities [3,4]. The imidazole ring is found in very significant endogenous biomolecules, such as biotin, the autacoid histamine and the essential amino acid histidine [5].…”

Section: Introductionmentioning

confidence: 99%

Preparation and Biological Activities of New Heterocyclic Azo Ligand and Some of Its Chelate Complexes

Al-Muhanaa¹,

Al-Khafagy²

2018

Nano BioMed ENG

View full text Add to dashboard Cite

New azo ligand, 2[(Aminoantipyren) azo]-4,5-bis(4-Methoxyphenyl)-H imidazole, (AAMPI) was prepared through coupling reaction of 4-amino antipyrine with 4,5-bis (4-methoxyphenyl) imidazole. Then, complexation of ligand with ions Co(II), Ni(II), Cu(II), Zn(II), Cd(II) and Hg(II) were prepared to yield six complexes. The optimal conditions were studied for all complexes in the mole ratio between metal:ligand (M:L) as of 1:2 in the general formula [M(L) 2 ]Cl 2 ·H 2 O. Present results found the azo ligand was tridentate. The structures of ligand with complexes were identified by ultravioletvisible spectroscopy (UV-Vis), Fourier-transform infrared spectroscopy (FT-IR), proton nuclear magnetic resonance ( 1 HNMR), carbon-13 nuclear magnetic resonance ( 13 CNMR), mass spectrometry, elemental analysis (CHN), magnetic susceptibility and molar conductance. All the complexes exhibit octahedral geometry around the metal center. The antibacterial activities of synthesized compound were tested against the gram-negative, gram-positive bacteria and fungus. The results showed that the metal complexes exhibited antibacterial and antifungal activities compared with free ligand.

show abstract

“…Thiazoles are five-membered heterocyclic aromatic compound which was first prepared by A. Hantzsch [1] in 1888. The ability of aminothiazoles to form protontransfer complexes was developed in order to gain structural information enabling a study of the effect of amino group on 2-aminohistamine derivatives [2,3]. The synthesis of 2-aminothiazoles derivatives has several problems including low yield, harsh reactions, difficult isolation procedures, use of expensive catalysts [4][5][6] and so on.…”

Section: Introductionmentioning

confidence: 99%

Preparation and Biological Activities of Some Heterocyclic Compounds Derivatives from 2-Aminothiazoles

Al-Rammahi¹

2018

Nano BioMed ENG

View full text Add to dashboard Cite

In the current investigation, two series of 2-amino thiazole derivatives were prepared. The first series involved synthesis of (Z)-3-(thiazol-2-ylimino)indolin-2-one (A1) as Schiff base derivatives of 2-amino thiazole and isatin, then synthesis of compounds A5, A6 and A7 as five membered rings (imidazolidins) by using different amino acids, and synthesis of compounds A3 and A4 as seven membered rings (1,3-oxazepine-di-one) by using maleic and phthalic anhydrides respectively. In the second series, 2-amino thiazole was treated with acetyl acetone to form (2E,4E)-N2,N4-di(thiazol-2-yl) pentane-2,4-diimine (A2) as di-Schiff base derivatives, and finally the preparation of imidazolidin (A8) by using 2 mol of tyrosine and preparation of tetrazole derivative (A9) by using 2 mol of sodium azide. The biological study for the above two series indicated that both gram-negative and grampositive activities were noticed.

show abstract

Synthesis, structure, DNA binding and anticancer activity of mixed ligand ruthenium(II) complex

Cited by 10 publications

References 35 publications

Ruthenium(II) and Iridium(III) Complexes as Tested Materials for New Anticancer Agents

Ruthenium(II) and Iridium(III) Complexes as Tested Materials for New Anticancer Agents

Preparation and Biological Activities of New Heterocyclic Azo Ligand and Some of Its Chelate Complexes

Preparation and Biological Activities of Some Heterocyclic Compounds Derivatives from 2-Aminothiazoles

Contact Info

Product

Resources

About